Skip to content

The 4th Annual Gene Therapy for Rare Disorders will focus exclusively on overcoming the late-stage commercial challenges drug developers face when delivering gene therapies to market.

With approvals in a number of indications over the last year, and more rapidly approaching on the horizon, the meeting will leverage the experience from first to market pioneers, as well as unveiling the strategies
drug developers are employing to improve efficacy, safety and commercial viability.

Incorporating insights from 80+ industry-leading speakers, this conference will delve into the key regulatory, reimbursement, clinical and manufacturing hurdles that need to be overcome to realize the commercial potential of gene therapies.

Join 600+ of your colleagues to accelerate the progress of the next generation of gene therapies.

This is your comprehensive guide to define your commercial path forward in 2020.

 

Access the official 2020 agenda to see the topics that will be addressed.

World-Class Speaking Faculty

Pamela Bradt

CSO

ICER

Katherine Dallow

VP, Clinical Programs & Strategy

Blue Cross Blue Shield of Massachusetts

Kei Kishimoto

CSO

Selecta Biosciences

Luis Maranga

CTOO

Voyager Therapeutics

Peter Marks

Director, CBER

FDA

Chris Mason

CSO

AvroBio

Emily McGinnis

VP, Patient Advocacy & Professional Relations

AveXis

Federico Mingozzi

CSO

Spark Therapeutics

Other Events in the Gene Therapy Series